Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 15 Mar 2016
Revised: 29 Aug 2016
Accepted: 30 Aug 2016
First published online: 25 Sep 2016

Article Access Statistics
Abstract Page Views: 365
PDF Downloads: 221
Full Text Views: 0

Adv Pharm Bull. 2016;6(3):407-413 doi: 10.15171/apb.2016.053

Preparation and Bioavailability Analysis of Ferrous Bis Alanine Chelate as a New Micronutrient for Treatment of Iron Deficiency Anemia

Research Article

Marzieh Zargaran 1, Ebrahim Saadat 1, Rassoul Dinarvand 1, Mohammad Sharifzadeh 2, Farid Dorkoosh 1 *

1 Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14399-56131, Iran.
2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155–6451 Iran.



Abstract

Purpose: One of the most nutritional disorders around the world is iron deficiency. A novel iron compound was synthesized by chelating ferrous ions with alanine for prevention and treatment of iron deficiency anemia.

Methods: The newly synthesized compound was characterized both qualitatively and quantitatively by Fourier Transform Infrared (FT-IR) spectroscopy. The bioavailability of newly synthesized iron micronutrient was evaluated in four groups of Wistar rats. The group I was a negative control group and the other three groups received three different iron formulations. After 14 days, the blood samples were taken and analyzed accordingly.

Results: Calculations showed that more than 91.8% of iron was incorporated in the chelate formulation. In vivo studies showed that serum iron, total iron binding capacity and hemoglobin concentrations were significantly increased in group IV, which received ferrous bis alanine chelate compared with the negative control group (p<0.05) and also group II, which received ferrous sulfate.7H2O (p<0.05). It indicates that the new formulation considerably improves the blood iron status compared with the conventional iron compounds. There were no significant differences (p<0.05) in the serum iron between group IV and group III, which received ferrous bis glycine.

Conclusion: The results showed better bioavailability of ferrous bis alanine as a new micronutrient for treatment of iron deficiency anemia in comparison with ferrous sulfate. Ferrous bis alanine could be considered as a suitable supplement for prevention and treatment of iron deficiency anemia.







Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Zargaran M
Articles by Saadat E
Articles by Dinarvand R
Articles by Sharifzadeh M
Articles by Dorkoosh F

PubMed
Articles by Zargaran M
Articles by Saadat E
Articles by Dinarvand R
Articles by Sharifzadeh M
Articles by Dorkoosh F



Share this article!

Press Manuscript Online. Powered by MAADRAYAN